Allspring Global Investments Holdings LLC Decreases Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

Allspring Global Investments Holdings LLC trimmed its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 31.0% in the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 768,512 shares of the medical research company's stock after selling 345,236 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.57% of Natera worth $108,091,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Global Retirement Partners LLC boosted its stake in shares of Natera by 55.0% during the 4th quarter. Global Retirement Partners LLC now owns 434 shares of the medical research company's stock worth $69,000 after purchasing an additional 154 shares during the period. Proficio Capital Partners LLC purchased a new stake in Natera in the fourth quarter valued at approximately $16,113,000. Williamson Legacy Group LLC boosted its stake in shares of Natera by 3.6% in the fourth quarter. Williamson Legacy Group LLC now owns 8,994 shares of the medical research company's stock worth $1,424,000 after buying an additional 312 shares during the last quarter. West Michigan Advisors LLC acquired a new position in shares of Natera in the fourth quarter worth about $616,000. Finally, Bridges Investment Management Inc. purchased a new stake in shares of Natera in the fourth quarter valued at approximately $252,000. 99.90% of the stock is currently owned by institutional investors.

Insider Transactions at Natera

In other Natera news, Director Gail Boxer Marcus sold 4,000 shares of the stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $164.44, for a total value of $657,760.00. Following the transaction, the director directly owned 5,704 shares in the company, valued at approximately $937,965.76. This trade represents a 41.22% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Solomon Moshkevich sold 3,000 shares of the firm's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $157.07, for a total transaction of $471,210.00. Following the sale, the insider owned 133,205 shares in the company, valued at approximately $20,922,509.35. The trade was a 2.20% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 40,630 shares of company stock valued at $6,235,808. Company insiders own 7.60% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently commented on NTRA shares. Wall Street Zen downgraded Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. Morgan Stanley boosted their target price on Natera from $176.00 to $185.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Barclays lifted their price objective on shares of Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. UBS Group lifted their price target on shares of Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a research note on Friday, May 9th. Finally, Royal Bank Of Canada began coverage on shares of Natera in a research report on Thursday, March 13th. They issued an "outperform" rating and a $251.00 price target for the company. One investment analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $184.63.

Natera Stock Up 0.5%

Natera stock traded up $0.85 during mid-day trading on Wednesday, hitting $161.57. 1,082,171 shares of the stock were exchanged, compared to its average volume of 1,421,786. The firm's fifty day simple moving average is $159.78 and its two-hundred day simple moving average is $158.51. Natera, Inc. has a 12 month low of $92.14 and a 12 month high of $183.00. The stock has a market capitalization of $22.06 billion, a price-to-earnings ratio of -109.91 and a beta of 1.73.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, topping analysts' consensus estimates of ($0.59) by $0.09. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The firm had revenue of $501.83 million for the quarter, compared to the consensus estimate of $446.68 million. During the same quarter in the previous year, the business earned ($0.56) EPS. The company's revenue was up 36.5% compared to the same quarter last year. As a group, analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.